| Gene symbol | IL1RAP | Synonyms | C3orf13, IL-1RAcP, IL1R3 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q28 | dbXrefs | |
| Description | interleukin 1 receptor accessory protein | ||||
| GTO ID | GTC3773 |
| Trial ID | NCT06281847 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | IL1RAP |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CCTx-001 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia |
| Year | 2024 |
| Country | France|Germany|Spain|Sweden |
| Company sponsor | Advesya SAS |
| Other ID(s) | CCTx-001-AML-001 |
| Cohort 1 | |||||||
|
|||||||